Improving patient selection for immuno-oncology phase I trials: An external validation of five prognostic scores at Claudius Regaud Institute of Toulouse, Oncopôle (IUCT-O)
Ghassan Al Darazi(Institut Claudius Regaud), Carlos Gomez‐Roca(Université Fédérale de Toulouse Midi-Pyrénées), E. Martin(Institut de Cancérologie de l'Ouest), Iphigénie Korakis(Institut Claudius Regaud), Thomas Filleron(Institut universitaire du cancer de Toulouse Oncopole), Jean‐Pierre Delord, Florent Ollivier(Institut Claudius Regaud), Muriel Poublanc(Institut Claudius Regaud), Sarah Bétrian(Institut Claudius Regaud)
Cited by 1
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
|Journal of Thoracic Oncology|2019|437
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
|The Lancet Haematology|2016|431
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
|The Lancet Oncology|2014|410
Targeting RET in Patients With <i>RET</i>-Rearranged Lung Cancers: Results From the Global, Multicenter <i>RET</i> Registry
|Journal of Clinical Oncology|2017|357